Bacterial Extracellular Vesicles (EV): From Fundamental Studies to Innovative Applications

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology and Immunology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 4500

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry and Chemical Biology, College of Sciences, Northeastern University, Boston, MA 02115, USA
Interests: microbial ecology; biotechnology; growth kinetics and stoichiometry; fermentation; mathematical models of microbial growth; genome-scale metabolic reconstructions; history of microbiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In eukaryotes, vesicles were early recognized as essential structures performing trafficking, neuron action, hormone release, and other functions. In contrast, microbial EVs were initially misinterpreted as waste matter. Their role then was accepted for G-negative bacteria, and only recently extended to other prokaryotes and communities (gut, soil, aquatic). Bacterial EV formation is viewed as a dynamic, self-regulated, and purposeful process integral to microbial life. One notable aspect is the innovative biotherapeutic applications of EVs as vaccines, immunoadjuvants, antibacterial agents, drug delivery, etc.

This Special Issue opens a wide gate for experimental reports, reviews, and conceptual developments on microbial EVs based on facts, not speculations. Some examples:

  • Metabolic cost of vesiculation (V);
  • Kinetics of V and parallel fusion;
  • V strains variability;
  • Competitive benefit/disadvantage of cells with enhanced V;
  • EV’s role in the community.

The statement "There is nothing more practical than a good theory" suggests that a new fundamental understanding of EVs is equally valuable as innovative biotherapies.

Dr. Nicolai S. Panikov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 11015 KiB  
Article
Extracellular Membrane Vesicles of Escherichia coli Induce Apoptosis of CT26 Colon Carcinoma Cells
by Yao Jiang, Jing Ma, Yuqing Long, Yuxi Dan, Liaoqiong Fang and Zhibiao Wang
Microorganisms 2024, 12(7), 1446; https://doi.org/10.3390/microorganisms12071446 - 17 Jul 2024
Cited by 7 | Viewed by 3812
Abstract
Escherichia coli (E. coli) is commonly utilized as a vehicle for anti-tumor therapy due to its unique tumor-targeting capabilities and ease of engineering modification. To further explore the role of E. coli in tumor treatment, we consider that E. coli outer [...] Read more.
Escherichia coli (E. coli) is commonly utilized as a vehicle for anti-tumor therapy due to its unique tumor-targeting capabilities and ease of engineering modification. To further explore the role of E. coli in tumor treatment, we consider that E. coli outer membrane vesicles (E. coli-OMVs) play a crucial role in the therapeutic process. Firstly, E. coli-OMVs were isolated and partially purified by filtration and ultracentrifugation, and were characterized using techniques such as nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM) and Western Blot (WB). The obtained extracellular nanoparticles, containing OMVs, were found to inhibited the growth of CT26 tumor in mice, while the expression of Bax protein was increased and the expression of Bcl-2 protein decreased. In vitro experiments showed that E. coli-OMVs entered CT26 cells and inhibited cell proliferation, invasion and migration. In addition, in the presence of E. coli-OMVs, we observed an increase in apoptosis rate and a decrease in the ratio of Bcl-2/Bax. These data indicate that E. coli-OMVs inhibits the growth of CT26 colon cancer by inducing apoptosis of CT26 cells. These findings propose E. coli-OMVs as a promising therapeutic drug for colorectal cancer (CRC), providing robust support for further research in related fields. Full article
Show Figures

Figure 1

Back to TopTop